EIK1001 Phase 2 NSCLC Data Shows 63.1% ORR at ASCO, EIK1003 Also Active
EIKN sits 31% above its 52-week low of $7.9.
Summary
Eikon Therapeutics presented strong updated Phase 2 clinical data for its lead oncology candidate, EIK1001, at ASCO, achieving a 63.1% Overall Response Rate and 90.8% Disease Control Rate in NSCLC. The company also reported activity for EIK1003 in its Phase 1/2 trial. This follows an 8-K filing earlier today disclosing these positive results. These are highly significant results for the company's core pipeline, substantially de-risking its lead assets and potentially accelerating their path to market.
At the time of this announcement, EIKN was trading at $10.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.9M. The 52-week trading range was $7.90 to $17.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.